These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 6426240)

  • 21. [Hodgkin's disease: treatment of clinical stages II3+A, IB, IIB, IIIA and IIIB with short chemotherapy (3 MOPP, or 3 CVPP), splenectomy and limited irradiation. Results after 4 years of a prospective protocol including 94 patients].
    Andrieu JM; Casassus P; Coscas Y; Darmont J; Goubeau C; Katz M; Jacquillat C; Tricot G; Weil M
    Bull Cancer; 1982; 69(4):321-9. PubMed ID: 6897520
    [No Abstract]   [Full Text] [Related]  

  • 22. [Experience with the management of patients with therapy-resistant Hodgkin's disease].
    Berényi E; Szegedi G
    Orv Hetil; 1984 Nov; 125(45):2737-40, 2743. PubMed ID: 6548560
    [No Abstract]   [Full Text] [Related]  

  • 23. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial.
    Duggan DB; Petroni GR; Johnson JL; Glick JH; Fisher RI; Connors JM; Canellos GP; Peterson BA
    J Clin Oncol; 2003 Feb; 21(4):607-14. PubMed ID: 12586796
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Post-transfusion graft versus host disease in a patient with Hodgkin's disease].
    Tomás Martínez JF; Abad Hernández MJ; Cortina de la Calle MP; Canut Blasco A; Nieto González MJ; Corral Alonso M; San Miguel Izquierdo JF; López-Borrasca A
    Med Clin (Barc); 1989 Apr; 92(13):503-6. PubMed ID: 2747313
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Splenectomy effects on chemotherapy in Hodgkin's disease.
    Panettiere F; Coltman CA
    Arch Intern Med; 1973 Mar; 131(3):362-6. PubMed ID: 4688035
    [No Abstract]   [Full Text] [Related]  

  • 26. Acute erythroblastic leukemia terminating a very long-lasting (27 years) Hodgkin's disease.
    Mantovani G; Del Giacco GS; Marongiu F; Tognella S; Carassi UE
    Acta Haematol; 1982; 67(4):287-8. PubMed ID: 6810628
    [No Abstract]   [Full Text] [Related]  

  • 27. [Transfusion-associated graft-vs-host disease].
    Lillevang ST; Kristensen T
    Ugeskr Laeger; 1992 Oct; 154(43):2964-8. PubMed ID: 1462384
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Hodgkin's disease and AIDS. Presentation of 5 cases].
    García Alfonso P; Flores Sañudo E; Carrión Galindo R; Jara Sánchez C; Cosín Ochaita J
    Rev Clin Esp; 1988 Apr; 182(6):314-6. PubMed ID: 2457232
    [No Abstract]   [Full Text] [Related]  

  • 29. Salvage chemotherapy in Hodgkin's disease irradiation failures: superiority of doxorubicin-containing regimens over MOPP.
    Santoro A; Viviani S; Villarreal CJ; Bonfante V; Delfino A; Valagussa P; Bonadonna G
    Cancer Treat Rep; 1986 Mar; 70(3):343-8. PubMed ID: 2420444
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fatal graft-versus-host disease following transfusion of granulocytes from normal donors.
    Ford JM; Cullen MH; Lucey JJ; Tobias JS; Lister TA
    Lancet; 1976 Nov; 2(7996):1167-9. PubMed ID: 62996
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) salvage of mechlorethamine, vincristine, prednisone, and procarbazine (MOPP)-resistant advanced Hodgkin's disease.
    Piga A; Ambrosetti A; Todeschini G; Cetto G; Perona G; Cellerino R
    Cancer Treat Rep; 1984; 68(7-8):947-51. PubMed ID: 6204754
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HLA homozygosity and shared HLA haplotypes in the development of transfusion-associated graft-versus-host disease.
    Shivdasani RA; Anderson KC
    Leuk Lymphoma; 1994 Oct; 15(3-4):227-34. PubMed ID: 7866271
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hodgkin's disease in a patient after treatment for angioimmunoblastic lymphadenopathy.
    Melato M; Falconieri G; Giammarini Barsanti A; Mottola A
    Haematologica; 1983; 68(5):675-9. PubMed ID: 6416946
    [No Abstract]   [Full Text] [Related]  

  • 34. Prognostic factors in children with Hodgkin disease.
    Celkan T; Yildiz I
    Pediatr Blood Cancer; 2008 Nov; 51(5):712; author reply 712-3. PubMed ID: 18668513
    [No Abstract]   [Full Text] [Related]  

  • 35. [Drug therapy of Hodgkin's disease].
    Gallmeier WM; Bruntsch U
    Internist (Berl); 1981 May; 22(5):289-300. PubMed ID: 7019138
    [No Abstract]   [Full Text] [Related]  

  • 36. Transfusion associated graft versus host disease in an immunocompetent individual following coronary artery bypass grafting.
    Ahya R; Douglas JG; Watson HG
    Heart; 1998 Sep; 80(3):299-300. PubMed ID: 9875094
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined radiotherapy and chemotherapy in the treatment of Hodgkin's disease.
    Tubiana M; Mathé G
    Ser Haematol; 1973; 6(2):202-43. PubMed ID: 4206180
    [No Abstract]   [Full Text] [Related]  

  • 38. Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation.
    Mandigers CM; Verdonck LF; Meijerink JP; Dekker AW; Schattenberg AV; Raemaekers JM
    Bone Marrow Transplant; 2003 Dec; 32(12):1159-63. PubMed ID: 14647270
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A case of transfusion-associated graft-versus-host disease not prevented by white cell-reduction filters.
    Akahoshi M; Takanashi M; Masuda M; Yamashita H; Hidano A; Hasegawa K; Kasajima T; Shimizu M; Motoji T; Oshimi K
    Transfusion; 1992 Feb; 32(2):169-72. PubMed ID: 1542924
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Combination chemotherapy (MOPP) in 60 patients with Hodgkin's disease (five years results) (author's transl)].
    Lauria F; Baccarani M; Barbieri E; Fiacchini M; Gobbi M; Tura S; Baccarani M
    Haematologica; 1975 Mar; 60(1):73-84. PubMed ID: 806500
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.